CEO Executive AssistantPediatric drug development obligations have become a permanent and strategically significant feature of pharmaceutical regulatory planning. Both the European Medicines Agency’s Pediatric Investigation Plan (PIP) requirement and the FDA’s Pediatric Study Plan (PSP) framework, established under the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA), create legal obligations for pharmaceutical sponsors to develop and submit plans for studying their drugs in pediatric populations. Non-compliance can block approval of adult indications in the European Union and result in additional regulatory requirements in the United States.
Pharma CEO pediatric investigation plan time management is a governance challenge that is frequently underestimated. Pediatric regulatory requirements touch every NDA/BLA development program and many supplemental applications. The CEO who understands these requirements and ensures they are governed with appropriate rigor protects program timelines, fulfills legal obligations, and potentially creates access to additional pediatric market exclusivity. The CEO who treats pediatric requirements as a compliance afterthought risks adult indication approval delays that are entirely avoidable.
The EMA PIP Framework: EU Market Access Requirement
In the European Union, the Pediatric Regulation (EC No 1901/2006) requires pharmaceutical companies to submit a Pediatric Investigation Plan to the EMA’s Pediatric Committee (PDCO) before submitting a marketing authorization application for a new medicine, a new indication, a new pharmaceutical form, or a new route of administration. The PDCO reviews the PIP and issues an opinion on whether the proposed pediatric development plan is appropriate, and whether any deferrals or waivers are justified.
A compliant, PDCO-agreed PIP is a prerequisite for marketing authorization applications in the EU. Applications that do not include evidence of PDCO agreement on the PIP will not be validated for review. For companies planning simultaneous global submissions to EMA and FDA, the PIP timeline must be planned carefully to ensure PDCO agreement is obtained before the EMA submission.
The PIP requires the company to:
Specify the proposed pediatric indication. The PIP must describe the pediatric condition for which the medicine is being developed, the proposed pediatric age ranges (neonates, infants, children, adolescents), and the rationale for the proposed development approach.
Describe the pediatric study program. The PIP must describe the specific clinical studies, pharmacokinetic studies, and formulation development activities planned for the pediatric population. These studies must be scientifically appropriate for the pediatric age ranges and must be designed to generate data that supports a pediatric indication.
Justify deferrals or waivers. In some circumstances, pediatric development is appropriately deferred until adult data are available, or waived entirely because the disease does not affect the pediatric population or because the medicine would be unsafe for pediatric use. The CEO must ensure the regulatory affairs organization is pursuing deferrals or waivers where scientifically and legally justified, not defaulting to full pediatric development programs that are unnecessary.
The EMA provides Pediatric Investigation Plan guidance that specifies the procedural and scientific requirements. CEOs should be familiar with the procedural timelines: the PDCO opinion process takes 120 days, and complex PIPs may require multiple procedural steps.
FDA PSP Requirements: US Pediatric Development Planning
The FDA’s Pediatric Research Equity Act requires sponsors to submit an initial Pediatric Study Plan for any NDA or BLA submission for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration, unless a waiver or deferral is granted. The initial PSP must be submitted before the end of Phase 2 meetings (or earlier if the program does not have a Phase 2).
FDA’s Pediatric Review Committee (PeRC) reviews PSPs and provides written feedback to the sponsor. The PSP process is intended to be a dialogue between FDA and the sponsor about what pediatric development is necessary and appropriate, not a unilateral FDA mandate.
The CEO’s role in PSP governance:
Timing alignment with the adult program. The PSP must be submitted before the end-of-Phase 2 meeting, which means pediatric development planning must begin well before the adult Phase 3 program. The CEO must ensure the regulatory strategy includes explicit pediatric planning timelines that are integrated with the adult program timeline, not treated as a separate regulatory track to be addressed after the adult program is complete.
Waiver and deferral strategy. FDA grants full waivers when the disease does not occur in the relevant pediatric population, the medicine would be unsafe in that population, or development in that population would be highly impracticable. FDA grants deferrals when it is better to study the medicine in adults first before initiating pediatric studies. The CEO should ensure the regulatory team is pursuing appropriate waivers and deferrals where justified, because these can significantly simplify the development program without compromising regulatory compliance.
Pediatric formulation development. Pediatric clinical programs frequently require age-appropriate formulations: liquid formulations for young children, age-appropriate tablet sizes, pediatric-specific dosing devices. These formulation development activities require investment and lead time. The CEO must ensure pediatric formulation development is budgeted and prioritized appropriately within the overall development program.
Pediatric Exclusivity: The Commercial Upside
Both the US and EU frameworks provide commercial exclusivity incentives for pediatric development. In the United States, the BPCA provides six months of additional marketing exclusivity (attached to all existing patents and exclusivities) for sponsors who conduct pediatric studies requested by FDA through a Written Request, whether or not the pediatric studies are successful. This six-month exclusivity can be worth hundreds of millions of dollars for high-revenue products and is therefore a significant commercial incentive for voluntary pediatric development.
In the European Union, the Pediatric Regulation provides additional market protection periods for medicines that fulfill the PIP and obtain a pediatric indication. For products protected by a patent or SPC, six months of additional SPC extension is available. For orphan medicines, two years of additional market exclusivity is provided.
The CEO must ensure the organization’s pediatric regulatory strategy accounts for these exclusivity incentives. For high-revenue adult products, the calculation of whether to pursue voluntary pediatric development (above the PREA/BPCA mandatory requirements) based on the value of the additional exclusivity should be made at the CEO level, not delegated to regulatory affairs alone.
For a framework on managing regulatory exclusivity strategy, see orphan drug designation management.
PDCO and PeRC Interactions: CEO Engagement Strategy
The PDCO and PeRC are specialist committees with deep pediatric medicine expertise. Interactions with these committees require specific preparation and, for complex or contested PIP/PSP negotiations, may benefit from CEO-level engagement.
For standard PIP submissions where the PDCO’s initial opinion is consistent with the company’s proposed plan, the interaction is primarily a regulatory affairs function. For contested situations, where PDCO proposes requirements significantly different from the company’s PIP proposal, or where the company is seeking a waiver that the PDCO is questioning, a more senior approach is warranted.
In contested PIP situations, the CEO should be aware of:
The PDCO opinion and grounds for disagreement. The PDCO issues written opinions on PIPs that the company can accept or contest. Understanding the PDCO’s scientific reasoning is essential for deciding whether to contest the opinion and on what grounds.
Re-examination procedures. The EU Pediatric Regulation provides for re-examination of negative PDCO opinions. The re-examination process requires a detailed scientific response to the PDCO’s grounds for the negative opinion. CEO engagement in deciding whether to pursue re-examination and in setting the scientific strategy for the response is appropriate for contested PIP situations involving significant development burden.
Direct PDCO engagement. For complex PIPs, the PDCO may request an oral explanation meeting. These meetings benefit from senior sponsor representation. The CEO or CMO should lead the sponsor delegation in oral explanation meetings with PDCO.
Pediatric Pharmacokinetics: The Scientific Foundation
Pediatric drug development requires understanding that pediatric populations are not simply small adults. Pharmacokinetic parameters, including absorption, distribution, metabolism, and excretion, change significantly across pediatric age groups due to developmental changes in organ function, body composition, and enzyme expression. Drugs that are metabolized primarily by CYP3A4, for example, may have very different clearance rates in neonates (who have immature CYP3A4 expression) compared with older children or adults.
The CEO’s scientific engagement with pediatric programs should include understanding the pharmacokinetic rationale for the proposed pediatric dose regimen: why does the proposed pediatric dose (expressed as mg/kg or as a flat dose with weight-based ranges) adequately account for these developmental pharmacokinetic differences?
This level of scientific engagement positions the CEO to engage credibly with PDCO and PeRC reviewers, with pediatric KOLs, and with patient advocacy organizations that represent pediatric patient communities.
Pediatric Patient Advocacy: Relationship Management
Pediatric disease advocacy organizations are particularly emotionally and scientifically engaged stakeholders. In rare diseases with pediatric onset, patient advocacy organizations often represent the entire known patient community, have invested in natural history studies and patient registries, and have deeply personal relationships with the physicians and researchers who treat their children’s conditions.
For pharmaceutical companies with pediatric development programs, maintaining genuine relationships with pediatric patient advocacy organizations is both a scientific and ethical obligation. The CEO’s role:
Direct engagement with advocacy leadership. The CEO should maintain direct relationships with the executive directors and scientific advisory board chairs of the major patient advocacy organizations in each disease area where the company has pediatric programs.
Transparency about the pediatric development program. Patient advocacy organizations want to understand the company’s pediatric development plan: what studies are planned, what formulations will be developed, and what timeline is anticipated for pediatric data availability. The CEO should ensure this information is shared with advocacy organizations at an appropriate level, consistent with confidentiality obligations.
Community input into pediatric endpoint selection. Patient advocacy organizations often have the deepest understanding of what clinical outcomes matter most to pediatric patients and their families. Their input into the selection of primary and secondary endpoints for pediatric trials, consistent with FDA PRO guidance principles, is both scientifically valuable and relationship-building.
Time Architecture for Pediatric Program Governance
A practical time architecture for pharma CEO pediatric investigation plan time management:
Development program integration. Pediatric regulatory planning should be a standard agenda item in the Phase 2 portfolio review process, not a separate track. The CEO should ensure that every program approaching end-of-Phase 2 has a documented PSP strategy, and that programs approaching EU submission have PDCO-agreed PIPs.
Waiver and deferral review. The CEO should review the pediatric regulatory strategy for each active program annually, ensuring that waiver and deferral applications are being pursued where appropriate and that mandatory pediatric programs are properly resourced.
Contested PIP/PSP management. For any contested pediatric regulatory situation, the CEO should be briefed directly and should make the decision about escalation strategy and senior engagement.
Exclusivity value assessment. For high-revenue products approaching the BPCA Written Request consideration stage, the CEO should participate in the commercial assessment of pediatric exclusivity value.
Conclusion
Pharma CEO pediatric investigation plan time management reflects the reality that pediatric regulatory obligations are now a standard feature of global pharmaceutical development, not a special case. CEOs who integrate pediatric regulatory planning into the standard development program governance cycle, who govern PDCO and PeRC interactions with appropriate rigor, and who engage pediatric patient advocacy organizations with genuine transparency build pediatric programs that meet regulatory requirements, protect adult approval timelines, and create the additional exclusivity value that voluntary pediatric development can provide. The investment required is modest compared to the risk of adult approval delays that unmanaged pediatric regulatory obligations can create.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.